GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

denosumab   Click here for help

GtoPdb Ligand ID: 6886

Synonyms: AMG-162 | M05BX04 | Prolia® | Xgeva®
Approved drug
denosumab is an approved drug (FDA and EMA (2010))
Compound class: Antibody
Comment: Denosumab suppresses the activity of RANK ligand (RANKL), which normally promotes bone removal and resorption, but which becomes over active in many bone loss diseases.
Denosumab is produced from CHO cells stably expressing recombinant antibody component proteins [1]. It was the first RANKL inhibitor to be approved by the FDA.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
denosumab-bbdz; GP2411Jubbonti® and Rolcya®; Wyost®SandozEMA & FDA (2024-2025)Interchangeable with originator reference products Prolia® and Xgeva® respectively
denosumab-dssb; SB16Ospomyv®; Xbryk®; Obodence®Samsung BioepisEMA & FDA (2025)Referencing originator products Prolia® and Xgeva® respectively
denosumab-bmwo; CT-P41Stoboclo®; Osenvelt®CelltrionFDA & EMA (2025)Referencing originator products Prolia® and Xgeva® respectively
denosumab-bnht; FKS518Conexxence®; Bomyntra®Fresenius Kabi BiopharmaFDA (2025)Interchangeable with originator reference products Prolia® and Xgeva® respectively
denosumab-desuOsvyrti®; Jubereq®Accord HealthcareEMA & FDA (2025)Referencing originator products Prolia® and Xgeva® respectively
denosumab-mobz; MB09Izamby®/Boncresa®; Denbrayce®/Oziltus®mAbxience ResearchEMA & FDA (2025)Referencing originator products Prolia® and Xgeva® respectively
biosimilar denosumabEnwylma®; Zadenvi®ZentivaEMA (2025)Referencing originator products Prolia® and Xgeva® respectively
biosimilar denosumabJunod®; Yaxwer®Gedeon RichterEMA (2025)Referencing originator products Prolia® and Xgeva® respectively
biosimilar denosumab; Bmab1000Evfraxy®; Vevzuo®Biocon Biologics/Biosimilar Collaborations IrelandEMA & UK MHRA (2025)Referencing originator products Prolia® and Xgeva® respectively
denosumab-nxxpBildyos®; Bilprevda®SciencepharmaEMA, FDA & UK MHRA (2025)Referencing originator products Prolia® and Xgeva® respectively
biosimilar denosumabDenosumab IntasIntas PharmaceuticalsEMA (2025)Referencing originator product Prolia®
biosimilar denosumab Osqay®Enzene & Theramex Ireland LimitedEMA (2026)Referencing originator product Prolia®
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: denosumab

Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
RANK ligand Primary target of this compound Hs Antibody Binding >9.6 pIC50 - 1
⤷ pIC50 >9.6 (IC50 <2.3x10-10 M) [1]